子宫癌肉瘤的分子多样性:超越TP53
本研究对51例子宫癌肉瘤(UCS)患者进行基因组分析,分别分析癌与肉瘤成分。TP53改变最常见(88%),其次为PIK3CA(35%)和CCNE1(33%)。44例(84.6%)为TP53突变型,11例存在同源重组缺陷,7例(14%)肿瘤突变负荷高(≥16)。45例(88%)发现可能作为现有治疗分子靶点的改变。生存分析中无分子变量达统计学显著。
要点
- TP53改变见于88%的子宫癌肉瘤,TP53突变型占84.6%。
- 癌与肉瘤成分基因变异一致但拷贝数变异不同,支持单克隆起源。
- 45例(88%)存在可能靶向现有治疗的分子改变。
核心结论
- TP53突变型是最常见亚型,但子宫癌肉瘤仍存在分子异质性,揭示现有治疗的潜在靶点并强调分子谱分析在指导治疗中的作用。
- 癌与肉瘤成分的比较证实单克隆起源。
研究设计与样本
- 收集子宫癌肉瘤患者的临床和病理数据,对肿瘤DNA进行下一代测序以评估基因组改变、微卫星不稳定性、肿瘤突变负荷和同源重组缺陷。
- 共纳入51例患者,尽可能分别分析癌与肉瘤成分。
- 采用单因素Cox回归分析估计风险比。
主要发现
- TP53改变最常见(88%),其次为PIK3CA(35%)和CCNE1(33%)。
- 44例(84.6%)为TP53突变型;11例存在同源重组缺陷;7例(14%)肿瘤突变负荷高(≥16)。
- 癌与肉瘤成分显示一致的基因变异但拷贝数变异不同。
- 关键改变通路为TP53、RTK/RAS、PI3K和细胞周期通路;45例(88%)发现可能作为现有治疗分子靶点的改变。
- 生存分析中无分子变量达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study conducted genomic profiling of uterine carcinosarcoma (UCS) to gain molecular insights, analyzing carcinoma and sarcoma components separately when possible. METHODS: Clinical and pathological data from UCS patients were collected, and tumor DNA was analyzed using next-generation sequencing to evaluate genomic alterations, microsatellite instability, tumor mutational burden (TMB), and homologous recombination deficiency (HRD). Gene alterations were investigated within relevant cancer pathways, and the therapeutic potential was assessed. Lastly, univariate Cox regression analyses estimated hazard ratios. RESULTS: Among 51 included patient, TP53 was most frequently altered (88 %), followed by PIK3CA (35 %) and CCNE1 (33 %). Separate analysis of carcinoma and sarcoma components revealed concordant gene variants but divergent copy number variations. Based on molecular classification, the majority of the cases 44 (84.6 %) had a TP53mutant profile. Additionally, 11 cases were HR deficient, and 7 samples (14 %) had high TMB (≥16). Key altered pathways were TP53, RTK/RAS, PI3K, and cell cycle pathways. Altogether, alterations that could serve as possible molecular targets for existing therapies were identified in 45 cases (88 %). No molecular variables was statistical significant in the survival analysis. CONCLUSION: Although, the TP53-mutant profile was the most common subtype, UCS remains molecularly heterogeneous, revealing potential targets for existing therapies and emphasizing the role of molecular profiling in guiding treatment in UCS. Our comparison of the carcinoma and sarcoma components confirms a monoclonal origin. Despite its molecular heterogeneity, these findings highlight potential targets for existing therapies and emphasize the role of molecular sequencing in guiding treatment in UCS.
引用
- Pham ENB, van den Berg CB, Kokke NCCJ, et al. Molecular diversity in uterine carcinosarcoma: Beyond TP53. Gynecol Oncol. 2025. PMID: 40446429. doi:10.1016/j.ygyno.2025.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。